TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16003041
Drug: Left ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left ventricular volume (mL/m)
Study: 16003041
Drug: Left atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left atrial volume (mL/m)
Study: 16003041
Drug: Stroke volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroke volume (mL/m)
Study: 8398323
Drug: Salvage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage treatment after local recurrence
Study: 3962762
Drug: 5000 units
Normalized name: A-25, 25000 units oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 units calcium heparin subcutaneously 8-hourly for two weeks
Study: 31613046
Drug: Preprocedural anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprocedural anticoagulation (63% of patients, primarily intravenous unfractionated heparin)
Study: 30214185
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI (glycopyrrolate/formoterol fumarate, 18/9.6 μg, twice daily)
Study: 27619983
Drug: ipragliflozin (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipragliflozin (50-100 mg once daily)
Study: 27619983
Drug: control (continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: control (continuation of conventional therapy)
Study: 24862215
Drug: Rilpivirine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilpivirine long-acting (RPV-LA) 300 mg
Study: 24862215
Drug: Rilpivirine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilpivirine long-acting (RPV-LA) 600 mg
Study: 24862215
Drug: Rilpivirine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilpivirine long-acting (RPV-LA) 1,200 mg
Study: 12628949
Drug: Ramipril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (10 mg daily)
Study: 9061125
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation (400 mL daily during hospital stay and 200 mL daily for 6 months at home)
Study: 9061125
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual care without supplements)
Study: 30786835
Drug: JVS-100 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: JVS-100 8 mg
Study: 30786835
Drug: JVS-100 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: JVS-100 16 mg
Study: 29966016
Drug: SRLS 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRLS 100 mg
Study: 29966016
Drug: SRLS 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRLS 200 mg
Study: 29966016
Drug: SRLS 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRLS 400 mg
Study: 29966016
Drug: PLGA 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLGA 100 mg
Study: 17433902
Drug: Oral formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulations of female hormone replacement
Study: 15827780
Drug: Cytoreduction and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C (35 mg/m2) at 40-41 degrees C for 90 minutes
Study: 12221381
Drug: 60% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60% lidocaine gel
Study: 10547222
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 40 mg orally 15 minutes before thrombolysis, followed by 20 mg every 8 hours
Study: 31766063
Drug: Improvement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improvement of 25(OH)D levels from <75 nmol/l to ≥75 nmol/l (median: 40.2 nmol/l to 83.2 nmol/l)
Study: 31766063
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with consistently <75 nmol/l 25(OH)D levels
Study: 21311765
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid with low prevalence of antiplatelet therapy (60% on average)
Study: 21311765
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid with high prevalence of antiplatelet therapy (91% on average)
Study: 17284097
Drug: Remifentanil (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (bolus of 1.0 microg/kg, continuous infusion from 0.25 to 0.05 microg/kg/min)
Study: 17284097
Drug: Alfentanil (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (bolus of 10 microg/kg, continuous infusion from 2.0 to 0.5 microg/kg/min)
Study: 12039615
Drug: Psychotropic analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic analgesic nitrous oxide (PAN)
Study: 1827098
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg 12-hourly for 14 days
Study: 1827098
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate 500 mg 6-hourly for 14 days
Study: 7178675
Drug: Neo‐Biphyllin Mikroklysma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo‐Biphyllin Mikroklysma (400 mg Theophylline, 600 mg Diprophylline, 600 mg Proxyphylline)
Study: 29943872
Drug: 6-week knee
Normalized name: BOS TAURUS KNEE JOINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week knee extensor training program (twice-weekly, five sets of 12 stretches, 3 seconds per stretch)
Study: 20018300
Drug: Thiopental (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (1 mg/kg)
Study: 17963857
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive with 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate
Study: 17963857
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive with 30 mcg ethinyl estradiol and 3 mg drospirenone
Study: 12407615
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine and nimesulide combination
Study: 12407615
Drug: Epidural bupivacaine/fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine/fentanyl combination
Study: 10517037
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) morphine tablets (every 12 h)
Study: 10517037
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) morphine tablets (every 6 h)
Study: 8540930
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEPO) 150 U/kg administered intravenously twice a week for 4 weeks in group A (26 infants)
Study: 8540930
Drug: Erythrocyte transfusion
Normalized name: erythrocytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythrocyte transfusion when hemoglobin levels were less than 10 g/dL with symptoms or less than 8 g/dL in group B (25 infants)
Study: 2084936
Drug: Fixed minidose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed minidose warfarin (1 mg daily)
Study: 2084936
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (warfarin and placebo)
Study: 19797501
Drug: 1 microg
Normalized name: Alpha 1 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microg ACTH (1‐24) administered in the morning
Study: 19797501
Drug: 1 microg
Normalized name: Alpha 1 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microg ACTH (1‐24) administered in the afternoon
Study: 15924803
Drug: Xuezhikang (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang (0.6 g Bid)
Study: 11978847
Drug: [11C]NNC 112
Approvals — FDA: no, EMA: no, PMDA: no
Description: [11C]NNC 112 (D1 receptor antagonist)
Study: 7649665
Drug: Terminalia Arjuna
Normalized name: terminalia arjuna
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terminalia Arjuna (500 mg 8-hourly)
Study: 362141
Drug: RA27/3 rubella
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA27/3 rubella vaccine (Almevax)
Study: 362141
Drug: Cendehill vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cendehill vaccine (Cedevax)
Study: 29029224
Drug: HZ/su vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZ/su vaccine coadministered with IIV4
Study: 22013790
Drug: Dengzhan Xixin
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dengzhan Xixin Injection + Chinese decoction + Dengzhan Shengmai Capsule + acupuncture + massage + external washing with Chinese medicine
Study: 22013790
Drug: Kudiezi Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kudiezi Injection + Chinese decoction + Naoshuantong Capsule + acupuncture + massage + external washing with Chinese medicine
Study: 22013790
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine control (rehabilitation training and electronic stimulus)
Study: 18203894
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g UHV-HPMC
Study: 18203894
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g HV-HPMC
Study: 18203894
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g HV-HPMC
Study: 18203894
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g MC
Study: 18203894
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 g cellulose)
Study: 10521098
Drug: Single IUI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IUI 34 hours after hCG administration (Group A)
Study: 10521098
Drug: Double IUI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double IUI 12 hours and 34 hours after hCG administration (Group B)
Study: 10521098
Drug: Double IUI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double IUI 34 hours and 60 hours after hCG administration (Group C)
Study: 8622099
Drug: Isepamicin once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isepamicin once daily plus ceftriaxone
Study: 8622099
Drug: Amikacin twice
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin twice daily plus ceftriaxone
Study: 1828561
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (3 mg daily for 16 weeks)
Study: 1828561
Drug: Lactose (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (placebo, 3 mg daily for 16 weeks)
Study: 29306619
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of glucose 10% (50 g glucose)
Study: 29306619
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of 2% lipid emulsion (soybean 30%, medium chain triglycerides (TG) 30%, olive oil 25%, fish oil 15%, and 20 mg vitamin E)
Study: 23937849
Drug: Indapamide sustained
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide sustained release tablets and Perindopril
Study: 11104589
Drug: Alanyl-glutamine supplementation
Normalized name: Alanyl glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alanyl-glutamine supplementation (0.5 g/kg BW/day)
Study: 9046717
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg intramuscularly
Study: 9046717
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg intramuscularly
Study: 8314685
Drug: Pravastatin 20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20-40 mg/day given at bedtime
Study: 31352467
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy (n=25; female/male=24/1)
Study: 23098346
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Losartan 100 mg/Hydrochlorothiazide 25 mg)
Study: 20631555
Drug: 10‐mg aripiprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg aripiprazole for 2 weeks
Study: 18346606
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg and placebo
Study: 18346606
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg and ranitidine 150 mg
Study: 18346606
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg and metoclopramide 10 mg
Study: 15934081
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with NSAIDs
Study: 15934081
Drug: On-demand treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand treatment with NSAIDs
Study: 12870201
Drug: Flutrimazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutrimazole 1% powder applied twice daily for 4 weeks
Study: 12870201
Drug: Bifonazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole 1% powder applied twice daily for 4 weeks
Study: 10895107
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation (two oral supplements each day during hospital stay)
Study: 1541318
Drug: Pinacidil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil (25 to 100 mg daily for 8 weeks)
Study: 22878539
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection into neck area
Study: 22878539
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection into thigh muscle
Study: 11405173
Drug: Combined adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined adjuvant 5‐fluorouracil‐based chemotherapy and radiotherapy
Study: 9272360
Drug: Acellular vaccines
Normalized name: PERTUSSIS VACCINE,ACELLULAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular vaccines (Chiron Biocine three-component and SmithKline Beecham three-component)
Study: 9272360
Drug: Whole-cell study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell study vaccine (produced by Connaught Laboratories, Inc.)
Study: 7944455
Drug: Intra-lymph nodal
Normalized name: Bos taurus lymph preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-lymph nodal injection of MMC-CH 40
Study: 3277804
Drug: Nebulized terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized terbutaline (10 mg)
Study: 3277804
Drug: Intravenous enprofylline
Normalized name: etofylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enprofylline (2 mg/kg)
Study: 23117243
Drug: Glucocorticoid (GC)
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid (GC) bridging therapy response at 2 weeks
Study: 23117243
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy arms and baseline DAS
Study: 21402164
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg D-cycloserine (DCS)
Study: 21402164
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg valproic acid (VPA)
Study: 21402164
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 100 mg DCS and 400 mg VPA
Study: 15635596
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with newer agents (e.g., taxanes)
Study: 10518852
Drug: Herbal Mouth
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal Mouth and Gum Therapy
Study: 8124953
Drug: IL‐1ra 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1ra 17 mg/hr
Study: 8124953
Drug: IL‐1ra 67
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1ra 67 mg/hr
Study: 8124953
Drug: IL‐1ra 133
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1ra 133 mg/hr
Study: 8124953
Drug: IL‐1ra treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1ra treatment in septic shock
Study: 8124953
Drug: IL‐1ra treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1ra treatment in Gram-negative infection
Study: 8124953
Drug: IL‐1ra treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1ra treatment in patients with IL‐6 > 100 pg/mL
Study: 8124953
Drug: IL‐1ra treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1ra treatment
Study: 2536789
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of RIT 4237 attenuated rotavirus vaccine
Study: 2536789
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of RIT 4237 attenuated rotavirus vaccine
Study: 30180087
Drug: Glutamate injection
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate injection (1 mol/L or 0.25 mol/L)
Study: 24507766
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with a mean dose to the whole and inferior rectum
Study: 24507766
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with a median volume of rectum treated to ≥70 Gy (V70)
Study: 24507766
Drug: Low (V25-V40),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low (V25-V40), intermediate (V50-V60), and high (V70-V80) doses to the inferior rectum
Study: 24507766
Drug: Highest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest dose (V80) to the mid-rectum
Study: 18759650
Drug: Sertraline (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (n = 13)
Study: 12968980
Drug: Laxatives
Normalized name: LAXATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxatives
Study: 12968980
Drug: Anticholinergic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic and antispasmodic agents
Study: 10579482
Drug: 0.8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg/kg dextromethorphan
Study: 10579482
Drug: 1.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg/kg dextromethorphan
Study: 10579482
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg dextromethorphan
Study: 10579482
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg dextromethorphan
Study: 10579482
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg dextromethorphan
Study: 8841152
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg dextromethorphan
Study: 7574017
Drug: Propofol (1.5‐2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5‐2.0 mg/kg, intravenously) + nitrous oxide 60% in oxygen + propofol infusion (75‐160 micrograms.kg‐1.min‐1 IV)
Study: 7574017
Drug: Propofol (1.5‐2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5‐2.0 mg/kg, intravenously) + nitrous oxide 60% in oxygen + sevoflurane (1%‐2% end‐tidal)
Study: 1817766
Drug: Class 1C
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class 1C antiarrhythmic drugs
Study: 1817766
Drug: Non-pharmacological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological treatments (catheter ablation and surgery)
Study: 1817766
Drug: Class 1A
Normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Class 1A antiarrhythmic drugs (disopyramide or quinidine)
Study: 6271841
Drug: Topical delta
Normalized name: Delta Tritex Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical delta 9-tetrahydrocannabinol (THC) in light mineral oil vehicles (0.05% and 0.1% solutions)
Study: 31164169
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 2400 mg oral, delivered as a take-home medication for 12 weeks
Study: 31164169
Drug: Placebo, matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, matched to NAC, delivered as a take-home medication for 12 weeks
Study: 29801063
Drug: IAI monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAI monotherapy
Study: 25252192
Drug: mpHBV (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: mpHBV (1 mL intramuscular dose containing 40 μg HBsAg)
Study: 25252192
Drug: Licensed hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed hepatitis B vaccine (1 mL intramuscular dose as two injections, each containing 20 μg HBsAg; total 40 μg HBsAg)
Study: 22762143
Drug: LAM+DNA vaccine
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM+DNA vaccine
Study: 22762143
Drug: LAM monotherapy
Normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LAM monotherapy
Study: 20054409
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRHa) treatment with leuprolide acetate (3.75 mg) subcutaneously every 4 weeks during chemotherapy
Study: 18312044
Drug: Quetiapine (100-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (100-800 mg/day)
Study: 18312044
Drug: Risperidone (0.5-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.5-4 mg/day)
Study: 12115174
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg infliximab every 8 weeks
Study: 12115174
Drug: Decreasing dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreasing dosing interval from 8 weeks to 6 weeks
Study: 9834004
Drug: Generic carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic carbamazepine formulations